Startseite » Forschung » Studien Finasterid » Neue Studie? (Fin im Vergleich)
alex33 ist gerade offline  alex33
Neue Studie? [Beitrag #250035] :: Di., 11 Dezember 2012 22:06 Zum vorherigen Beitrag gehen
Kann jemand diese Studie verständlich erklären? danke Wink

J Med Assoc Thai. 2012 Oct;95(10):1312-6.
Efficacy and safety of 3% minoxidil versus combined 3% minoxidil / 0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study.
Tanglertsampan C.
Source

Department of Dermatology, School of Anti-aging and Regenerative Medicine, Mae Fah Luang University Hospital (Bangkok), Bangkok, Thailand. drchuchait@yahoo.com
Abstract
BACKGROUND:

Topical minoxidil and oral finasteride have been used to treat men with androgenetic alopecia (AGA). There are concerns about side effects of oral finasteride especially erectile dysfunction.
OBJECTIVE:

To compare the efficacy and safety of the 24 weeks application of 3% minoxidil lotion (MNX) versus combined 3% minoxidil and 0.1% finasteride lotion (MFX) in men with AGA.
MATERIAL AND METHOD:

Forty men with AGA were randomized treated with MNX or MFX. Efficacy was evaluated by hair counts and global photographic assessment. Safety assessment was performed by history and physical examination.
RESULTS:

At week 24, hair counts were increased from baseline in both groups. However paired t-test revealed statistical difference only in MFX group (p = 0.044). Unpaired t-test revealed no statistical difference between two groups with respect to change of hair counts at 24 weeks from baseline (p = 0.503). MFX showed significantly higher efficacy than MNX by global photographic assessment (p = 0.003). There was no significant difference in side effects between both groups.
CONCLUSION:

Although change of hair counts was not statistically different between two groups, global photographic assessment showed significantly greater improvement in the MFX group than the MNX group. There was no sexual side effect. MFX may be a safe and effective treatment option.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23193746

[Aktualisiert am: Di., 11 Dezember 2012 22:07]

Den Beitrag einem Moderator melden

 Eine private Nachricht an diesen Benutzer verschicken  
 
[Beitragsindex]
 
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Vorheriges Thema: Aktuelle Studienauswertung zu 5-Alphareduktasehemmer
Nächstes Thema: haarausfall, prostatakrebs, DHT, Fin
Gehe zum Forum:
  

[ Themen als Syndikate anderen Seiten zur Verfügung stellen (XML) ] [ RSS ] [ PDF ]

aktuelle Zeit: Fr. Jul 19 20:18:59 MESZ 2024

Insgesamt benötigte Zeit, um die Seite zu erzeugen: 0.02841 Sekunden
Letzte 10 Themen



Videos / Infos
Video Schuppen / seborrhoisches Ekzem


Partner Hairforlife FUE EUROPE
» Neurodermitis :: » ADS (ADHS) :: Impressum / Datenschutz
.:: Kontakt :: Forumsindex ::.

Betrieben mit: FUDforum 3.1.3.
Copyright ©2001-2023 FUDforum Bulletin Board Software